Koesten, Hirschmann & Crabtree, Inc. Bristol Myers Squibb CO Transaction History
Koesten, Hirschmann & Crabtree, Inc.
- $156 Billion
- Q1 2024
A detailed history of Koesten, Hirschmann & Crabtree, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Koesten, Hirschmann & Crabtree, Inc. holds 1,418 shares of BMY stock, worth $58,889. This represents 0.05% of its overall portfolio holdings.
Number of Shares
1,418
Previous 1,380
2.75%
Holding current value
$58,889
Previous $70.8 Million
8.6%
% of portfolio
0.05%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding BMY
# of Institutions
2,554Shares Held
1.49BCall Options Held
25.9MPut Options Held
20M-
Vanguard Group Inc Valley Forge, PA186MShares$7.73 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY163MShares$6.75 Billion0.21% of portfolio
-
State Street Corp Boston, MA91.6MShares$3.8 Billion0.23% of portfolio
-
Jpmorgan Chase & CO New York, NY88.8MShares$3.69 Billion0.44% of portfolio
-
Capital International Investors Los Angeles, CA70.2MShares$2.92 Billion0.79% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $88.3B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...